drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01010 | DB01035 | 61 | 1,401 | [
"DDInter622",
"DDInter1524"
] | Edrophonium | Procainamide | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | A derivative of procaine with less CNS action. | Moderate | 1 | [
[
[
61,
24,
1401
]
],
[
[
61,
6,
5765
],
[
5765,
45,
1401
]
],
[
[
61,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
61,
24,
770
],
[
770,
... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Edrophonium",
"{u} (Compound) binds {v} (Gene)",
"ACHE"
],
[
"ACHE",
"{u} (Gene) is bound by {v} (Compound)",... | Edrophonium (Compound) binds ACHE (Gene) and ACHE (Gene) is bound by Procainamide (Compound)
Edrophonium (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Th... |
DB00794 | DB04845 | 759 | 309 | [
"DDInter1521",
"DDInter1001"
] | Primidone | Ixabepilone | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
759,
24,
309
]
],
[
[
759,
6,
8374
],
[
8374,
45,
309
]
],
[
[
759,
21,
29209
],
[
29209,
60,
309
]
],
[
[
759,
64,
1419
],
[
1419,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Primidone (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ixabepilone (Compound)
Primidone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a mod... |
DB00543 | DB01612 | 87 | 1,637 | [
"DDInter82",
"DDInter92"
] | Amoxapine | Amyl Nitrite | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
87,
24,
1637
]
],
[
[
87,
1,
686
],
[
686,
24,
1637
]
],
[
[
87,
63,
475
],
[
475,
24,
1637
]
],
[
[
87,
24,
401
],
[
401,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Amoxapine",
"{u} (Compound) resembles {v} (Compound)",
"Oxazepam"
],
[
"Oxazepam",
"{u} may cause a moderate in... | Amoxapine (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerb... |
DB08885 | DB11793 | 363 | 738 | [
"DDInter33",
"DDInter1297"
] | Aflibercept | Niraparib | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
363,
24,
738
]
],
[
[
363,
24,
496
],
[
496,
24,
738
]
],
[
[
363,
63,
66
],
[
66,
24,
738
]
],
[
[
363,
24,
1129
],
[
1129,
63,... | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]... | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Ef... |
DB00480 | DB08867 | 1,668 | 807 | [
"DDInter1035",
"DDInter1897"
] | Lenalidomide | Ulipristal | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
1668,
24,
807
]
],
[
[
1668,
24,
850
],
[
850,
63,
807
]
],
[
[
1668,
24,
478
],
[
478,
24,
807
]
],
[
[
1668,
63,
322
],
[
322,
... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with... |
DB06288 | DB09078 | 607 | 1,228 | [
"DDInter77",
"DDInter1036"
] | Amisulpride | Lenvatinib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
607,
25,
1228
]
],
[
[
607,
62,
112
],
[
112,
23,
1228
]
],
[
[
607,
64,
609
],
[
609,
24,
1228
]
],
[
[
607,
63,
770
],
[
770,
... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Amisulpride may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromyci... |
DB06589 | DB11718 | 1,250 | 927 | [
"DDInter1400",
"DDInter640"
] | Pazopanib | Encorafenib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1250,
24,
927
]
],
[
[
1250,
62,
112
],
[
112,
23,
927
]
],
[
[
1250,
24,
720
],
[
720,
24,
927
]
],
[
[
1250,
63,
216
],
[
216,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mine... |
DB00019 | DB00552 | 1,257 | 1,238 | [
"DDInter1405",
"DDInter1425"
] | Pegfilgrastim | Pentostatin | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Moderate | 1 | [
[
[
1257,
24,
1238
]
],
[
[
1257,
24,
1083
],
[
1083,
40,
1238
]
],
[
[
1257,
24,
1426
],
[
1426,
1,
1238
]
],
[
[
1257,
24,
1648
],
[
164... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) resembles Pentostatin (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Pentostat... |
DB01136 | DB11827 | 772 | 433 | [
"DDInter305",
"DDInter669"
] | Carvedilol | Ertugliflozin | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
772,
24,
433
]
],
[
[
772,
63,
959
],
[
959,
24,
433
]
],
[
[
772,
24,
820
],
[
820,
24,
433
]
],
[
[
772,
62,
1152
],
[
1152,
2... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alim... |
DB11057 | DB14881 | 720 | 180 | [
"DDInter1223",
"DDInter1329"
] | Mineral oil | Oliceridine | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
720,
24,
180
]
],
[
[
720,
24,
124
],
[
124,
24,
180
]
],
[
[
720,
63,
618
],
[
618,
24,
180
]
],
[
[
720,
63,
702
],
[
702,
25,... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abareli... |
DB00877 | DB09052 | 629 | 250 | [
"DDInter1678",
"DDInter220"
] | Sirolimus | Blinatumomab | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
629,
24,
250
]
],
[
[
629,
24,
949
],
[
949,
63,
250
]
],
[
[
629,
64,
1236
],
[
1236,
24,
250
]
],
[
[
629,
63,
599
],
[
599,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid a... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Sirolimus m... |
DB01009 | DB01225 | 935 | 500 | [
"DDInter1009",
"DDInter645"
] | Ketoprofen | Enoxaparin | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
935,
25,
500
]
],
[
[
935,
21,
28804
],
[
28804,
60,
500
]
],
[
[
935,
24,
1039
],
[
1039,
24,
500
]
],
[
[
935,
63,
305
],
[
305,
... | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Ketoprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Purpura"
],
[
"Purpura",
"{u} (Side Effect) is caused by {v} (Compound... | Ketoprofen (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Enoxaparin (Compound)
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with E... |
DB01115 | DB01177 | 336 | 77 | [
"DDInter1291",
"DDInter904"
] | Nifedipine | Idarubicin | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
336,
24,
77
]
],
[
[
336,
6,
6017
],
[
6017,
45,
77
]
],
[
[
336,
18,
6326
],
[
6326,
46,
77
]
],
[
[
336,
7,
15786
],
[
15786,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Nifedipine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Nifedipine (Compound) downregulates SLC25A4 (Gene) and SLC25A4 (Gene) is upregulated by Idarubicin (Compound)
Nifedipine (Compound) upregulates TCTN1 (Gene) and TCTN1 (Gene) is upregulated by Idarubicin (Compound)
Nifedipine (... |
DB06643 | DB11817 | 1,136 | 1,259 | [
"DDInter500",
"DDInter165"
] | Denosumab | Baricitinib | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
1136,
24,
1259
]
],
[
[
1136,
24,
384
],
[
384,
25,
1259
]
],
[
[
1136,
24,
1619
],
[
1619,
64,
1259
]
],
[
[
1136,
63,
367
],
[
367,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a... |
DB08882 | DB11255 | 1,281 | 1,371 | [
"DDInter1070",
"DDInter374"
] | Linagliptin | Chromium picolinate | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
1281,
24,
1371
]
],
[
[
1281,
63,
245
],
[
245,
24,
1371
]
],
[
[
1281,
24,
1296
],
[
1296,
24,
1371
]
],
[
[
1281,
40,
1002
],
[
1002... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin ... |
DB00405 | DB01589 | 128 | 481 | [
"DDInter517",
"DDInter1552"
] | Dexbrompheniramine | Quazepam | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
128,
24,
481
]
],
[
[
128,
24,
1216
],
[
1216,
1,
481
]
],
[
[
128,
63,
523
],
[
523,
1,
481
]
],
[
[
128,
63,
905
],
[
905,
40,... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Quazepam... |
DB09122 | DB12010 | 1,613 | 214 | [
"DDInter1409",
"DDInter785"
] | Peginterferon beta-1a | Fostamatinib | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1613,
24,
214
]
],
[
[
1613,
63,
866
],
[
866,
24,
214
]
],
[
[
1613,
24,
1155
],
[
1155,
24,
214
]
],
[
[
1613,
24,
159
],
[
159,
... | [
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cob... | Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00488 | DB06643 | 196 | 1,136 | [
"DDInter57",
"DDInter500"
] | Altretamine | Denosumab | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
196,
24,
1136
]
],
[
[
196,
25,
1377
],
[
1377,
24,
1136
]
],
[
[
196,
25,
1510
],
[
1510,
63,
1136
]
],
[
[
196,
24,
270
],
[
270,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunom... | Altretamine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Altretamine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a mode... |
DB00615 | DB08912 | 690 | 1,040 | [
"DDInter1589",
"DDInter462"
] | Rifabutin | Dabrafenib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
690,
24,
1040
]
],
[
[
690,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
690,
7,
3727
],
[
3727,
46,
1040
]
],
[
[
690,
18,
2183
],
[
2183,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Rifabutin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Dabrafenib (Compound)
Rifabutin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Dabrafenib (Compound)
Rifabutin (Compound) ... |
DB00285 | DB00975 | 1,100 | 1,317 | [
"DDInter1927",
"DDInter573"
] | Venlafaxine | Dipyridamole | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
1100,
24,
1317
]
],
[
[
1100,
6,
4973
],
[
4973,
45,
1317
]
],
[
[
1100,
21,
29296
],
[
29296,
60,
1317
]
],
[
[
1100,
24,
714
],
[
71... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Venlafaxine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dipyridamole (Compound)
Venlafaxine (Compound) causes Ventricular extrasystoles (Side Effect) and Ventricular extrasystoles (Side Effect) is caused by Dipyridamole (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate disease... |
DB01033 | DB01073 | 328 | 1,488 | [
"DDInter1156",
"DDInter745"
] | Mercaptopurine | Fludarabine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
328,
24,
1488
]
],
[
[
328,
63,
372
],
[
372,
1,
1488
]
],
[
[
328,
5,
11555
],
[
11555,
44,
1488
]
],
[
[
328,
6,
13418
],
[
13418,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound)
Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound)
Mercaptopurine (Compo... |
DB00694 | DB10315 | 51 | 1,137 | [
"DDInter485",
"DDInter1127"
] | Daunorubicin | Measles virus vaccine live attenuated | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
51,
25,
1137
]
],
[
[
51,
64,
581
],
[
581,
25,
1137
]
],
[
[
51,
24,
384
],
[
384,
25,
1137
]
],
[
[
51,
63,
1184
],
[
1184,
25... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Daunorubicin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idela... |
DB00911 | DB01024 | 458 | 1,096 | [
"DDInter1811",
"DDInter1252"
] | Tinidazole | Mycophenolic acid | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
458,
24,
1096
]
],
[
[
458,
63,
955
],
[
955,
1,
1096
]
],
[
[
458,
7,
4634
],
[
4634,
46,
1096
]
],
[
[
458,
21,
28666
],
[
28666,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofeti... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Tinidazole (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Mycophenolic acid (Compound)
Tinidazole (Compound... |
DB01138 | DB09054 | 804 | 384 | [
"DDInter1726",
"DDInter905"
] | Sulfinpyrazone | Idelalisib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
804,
24,
384
]
],
[
[
804,
63,
222
],
[
222,
23,
384
]
],
[
[
804,
25,
1618
],
[
1618,
24,
384
]
],
[
[
804,
63,
888
],
[
888,
2... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantini... |
DB00619 | DB01018 | 1,419 | 1,364 | [
"DDInter909",
"DDInter847"
] | Imatinib | Guanfacine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Major | 2 | [
[
[
1419,
25,
1364
]
],
[
[
1419,
63,
1512
],
[
1512,
1,
1364
]
],
[
[
1419,
6,
10215
],
[
10215,
45,
1364
]
],
[
[
1419,
21,
28757
],
[
2... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanfacine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Imatinib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Guanfacine (Compound)
Imatinib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Si... |
DB00422 | DB01069 | 895 | 401 | [
"DDInter1189",
"DDInter1533"
] | Methylphenidate | Promethazine | Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cogni... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
895,
24,
401
]
],
[
[
895,
24,
1264
],
[
1264,
63,
401
]
],
[
[
895,
24,
104
],
[
104,
24,
401
]
],
[
[
895,
6,
12523
],
[
12523,
... | [
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],... | Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine an... |
DB00059 | DB06754 | 1,560 | 707 | [
"DDInter1404",
"DDInter471"
] | Pegaspargase | Danaparoid | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
1560,
24,
707
]
],
[
[
1560,
24,
1496
],
[
1496,
63,
707
]
],
[
[
1560,
24,
901
],
[
901,
24,
707
]
],
[
[
1560,
24,
1468
],
[
1468,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and M... |
DB01234 | DB13928 | 1,220 | 1,385 | [
"DDInter513",
"DDInter1660"
] | Dexamethasone | Semaglutide | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1220,
24,
1385
]
],
[
[
1220,
40,
1103
],
[
1103,
23,
1385
]
],
[
[
1220,
64,
839
],
[
839,
24,
1385
]
],
[
[
1220,
24,
637
],
[
637,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Dexamethasone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exa... |
DB00277 | DB01064 | 1,031 | 1,148 | [
"DDInter1791",
"DDInter987"
] | Theophylline | Isoprenaline | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1031,
24,
1148
]
],
[
[
1031,
24,
480
],
[
480,
24,
1148
]
],
[
[
1031,
25,
1523
],
[
1523,
24,
1148
]
],
[
[
1031,
5,
11649
],
[
1164... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Theophylline may lead to a major life threatening interaction when taken with Labetalol and Labetalol may ca... |
DB00575 | DB01088 | 1,020 | 714 | [
"DDInter412",
"DDInter908"
] | Clonidine | Iloprost | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1020,
24,
714
]
],
[
[
1020,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1020,
24,
1450
],
[
1450,
63,
714
]
],
[
[
1020,
24,
274
],
[
274,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empag... |
DB00307 | DB11796 | 1,101 | 1,612 | [
"DDInter202",
"DDInter786"
] | Bexarotene | Fostemsavir | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Minor | 0 | [
[
[
1101,
23,
1612
]
],
[
[
1101,
23,
1051
],
[
1051,
23,
1612
]
],
[
[
1101,
25,
98
],
[
98,
23,
1612
]
],
[
[
1101,
62,
1324
],
[
1324,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Bexarotene may lead to a major life threatening interaction when taken with Somatrem and Somatrem may... |
DB00436 | DB00486 | 323 | 1,614 | [
"DDInter179",
"DDInter1253"
] | Bendroflumethiazide | Nabilone | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
323,
24,
1614
]
],
[
[
323,
24,
530
],
[
530,
1,
1614
]
],
[
[
323,
21,
28709
],
[
28709,
60,
1614
]
],
[
[
323,
40,
674
],
[
674,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Bendroflumethiazide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Nabilone (Compound)
Bendroflumet... |
DB06595 | DB10795 | 1,491 | 221 | [
"DDInter1214",
"DDInter1486"
] | Midostaurin | Poliovirus type 1 antigen (formaldehyde inactivated) | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1491,
24,
221
]
],
[
[
1491,
24,
36
],
[
36,
24,
221
]
],
[
[
1491,
64,
581
],
[
581,
24,
221
]
],
[
[
1491,
63,
599
],
[
599,
2... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Midostaurin may lead to a major life threatening interaction when taken w... |
DB00078 | DB00208 | 1,172 | 1,018 | [
"DDInter898",
"DDInter1804"
] | Ibritumomab tiuxetan | Ticlopidine | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Major | 2 | [
[
[
1172,
25,
1018
]
],
[
[
1172,
25,
1347
],
[
1347,
64,
1018
]
],
[
[
1172,
23,
539
],
[
539,
62,
1018
]
],
[
[
1172,
64,
1271
],
[
1271... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clo... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may caus... |
DB00902 | DB00915 | 104 | 1,170 | [
"DDInter1168",
"DDInter60"
] | Methdilazine | Amantadine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesi... | Moderate | 1 | [
[
[
104,
24,
1170
]
],
[
[
104,
24,
1532
],
[
1532,
63,
1170
]
],
[
[
104,
63,
1503
],
[
1503,
24,
1170
]
],
[
[
104,
40,
820
],
[
820,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amantadine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Amantadine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Linda... |
DB05294 | DB06176 | 1,069 | 1,342 | [
"DDInter1917",
"DDInter1616"
] | Vandetanib | Romidepsin | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
1069,
25,
1342
]
],
[
[
1069,
62,
1247
],
[
1247,
23,
1342
]
],
[
[
1069,
64,
956
],
[
956,
24,
1342
]
],
[
[
1069,
25,
1616
],
[
1616... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Vandetanib may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin ... |
DB00801 | DB01156 | 1,563 | 593 | [
"DDInter850",
"DDInter252"
] | Halazepam | Bupropion | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1563,
24,
593
]
],
[
[
1563,
63,
752
],
[
752,
23,
593
]
],
[
[
1563,
24,
1532
],
[
1532,
63,
593
]
],
[
[
1563,
40,
1216
],
[
1216,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
... | Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide ... |
DB01001 | DB06764 | 688 | 1,090 | [
"DDInter1632",
"DDInter1788"
] | Salbutamol | Tetryzoline (ophthalmic) | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
688,
24,
1090
]
],
[
[
688,
24,
1032
],
[
1032,
63,
1090
]
],
[
[
688,
24,
901
],
[
901,
24,
1090
]
],
[
[
688,
63,
1290
],
[
1290,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
... |
DB00486 | DB01178 | 1,614 | 369 | [
"DDInter1253",
"DDInter357"
] | Nabilone | Chlormezanone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Moderate | 1 | [
[
[
1614,
24,
369
]
],
[
[
1614,
24,
1532
],
[
1532,
63,
369
]
],
[
[
1614,
24,
272
],
[
272,
24,
369
]
],
[
[
1614,
63,
13
],
[
13,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and C... |
DB00443 | DB00819 | 251 | 471 | [
"DDInter195",
"DDInter15"
] | Betamethasone | Acetazolamide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
251,
24,
471
]
],
[
[
251,
24,
997
],
[
997,
40,
471
]
],
[
[
251,
6,
8374
],
[
8374,
45,
471
]
],
[
[
251,
21,
29232
],
[
29232,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Acetazolamide (Compound)
Betamethasone (Compound) causes Urticaria (Side ... |
DB00620 | DB01156 | 175 | 593 | [
"DDInter1855",
"DDInter252"
] | Triamcinolone | Bupropion | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
175,
25,
593
]
],
[
[
175,
6,
8374
],
[
8374,
45,
593
]
],
[
[
175,
7,
1870
],
[
1870,
57,
593
]
],
[
[
175,
18,
7359
],
[
7359,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bu... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Triamcinolone (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Bupropion (Compound)
Triamcinolone (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Bupropion (Compound)
Triamcin... |
DB00046 | DB00414 | 1,179 | 590 | [
"DDInter940",
"DDInter16"
] | Insulin lispro | Acetohexamide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
1179,
24,
590
]
],
[
[
1179,
23,
1103
],
[
1103,
23,
590
]
],
[
[
1179,
24,
651
],
[
651,
63,
590
]
],
[
[
1179,
24,
168
],
[
168,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],... | Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Acetohexamide
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin a... |
DB00910 | DB00930 | 1,041 | 166 | [
"DDInter1394",
"DDInter432"
] | Paricalcitol | Colesevelam | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | Moderate | 1 | [
[
[
1041,
24,
166
]
],
[
[
1041,
64,
160
],
[
160,
24,
166
]
],
[
[
1041,
25,
1196
],
[
1196,
63,
166
]
],
[
[
1041,
75,
1331
],
[
1331,
... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colesevelam"
]
],
[
[
"Paricalcitol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calcifediol"
],
[
"Calc... | Paricalcitol may lead to a major life threatening interaction when taken with Calcifediol and Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Colesevelam
Paricalcitol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may caus... |
DB00705 | DB09049 | 441 | 1,135 | [
"DDInter496",
"DDInter1261"
] | Delavirdine | Naloxegol | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
441,
25,
1135
]
],
[
[
441,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
441,
63,
1424
],
[
1424,
23,
1135
]
],
[
[
441,
25,
478
],
[
478,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} ma... | Delavirdine may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor i... |
DB00626 | DB01082 | 1,441 | 1,448 | [
"DDInter161",
"DDInter1713"
] | Bacitracin | Streptomycin | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Major | 2 | [
[
[
1441,
25,
1448
]
],
[
[
1441,
21,
28680
],
[
28680,
60,
1448
]
],
[
[
1441,
24,
1272
],
[
1272,
63,
1448
]
],
[
[
1441,
25,
361
],
[
3... | [
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
]
],
[
[
"Bacitracin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Bacitracin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Streptomycin (Compound)
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin
... |
DB00307 | DB00496 | 1,101 | 194 | [
"DDInter202",
"DDInter480"
] | Bexarotene | Darifenacin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Moderate | 1 | [
[
[
1101,
24,
194
]
],
[
[
1101,
24,
704
],
[
704,
1,
194
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
194
]
],
[
[
1101,
21,
29173
],
[
29173,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Darifenacin (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Darifenacin (Compound)
Bexarotene (Compound) causes Oedema peripheral (Side Effect) and Oed... |
DB00023 | DB08904 | 305 | 375 | [
"DDInter127",
"DDInter342"
] | Asparaginase Escherichia coli | Certolizumab pegol | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
305,
25,
375
]
],
[
[
305,
24,
231
],
[
231,
24,
375
]
],
[
[
305,
24,
200
],
[
200,
63,
375
]
],
[
[
305,
63,
491
],
[
491,
24,... | [
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate di... |
DB01263 | DB04845 | 859 | 309 | [
"DDInter1494",
"DDInter1001"
] | Posaconazole | Ixabepilone | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
859,
24,
309
]
],
[
[
859,
6,
8374
],
[
8374,
45,
309
]
],
[
[
859,
21,
28736
],
[
28736,
60,
309
]
],
[
[
859,
63,
1419
],
[
1419,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Posaconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Posaconazole (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Imatini... |
DB00046 | DB00104 | 1,179 | 966 | [
"DDInter940",
"DDInter1323"
] | Insulin lispro | Octreotide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Moderate | 1 | [
[
[
1179,
24,
966
]
],
[
[
1179,
24,
1154
],
[
1154,
1,
966
]
],
[
[
1179,
24,
772
],
[
772,
63,
966
]
],
[
[
1179,
24,
1101
],
[
1101,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide (Compound) resembles Octreotide (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction ... |
DB00775 | DB11689 | 1,226 | 321 | [
"DDInter1818",
"DDInter1659"
] | Tirofiban | Selumetinib | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
1226,
24,
321
]
],
[
[
1226,
64,
291
],
[
291,
24,
321
]
],
[
[
1226,
25,
498
],
[
498,
24,
321
]
],
[
[
1226,
25,
1421
],
[
1421,
... | [
[
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban"... | Tirofiban may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Tirofiban may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interacti... |
DB01050 | DB11166 | 848 | 18 | [
"DDInter900",
"DDInter104"
] | Ibuprofen | Antithrombin Alfa | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Moderate | 1 | [
[
[
848,
24,
18
]
],
[
[
848,
24,
714
],
[
714,
24,
18
]
],
[
[
848,
24,
738
],
[
738,
63,
18
]
],
[
[
848,
74,
1274
],
[
1274,
24,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nirapa... |
DB06589 | DB06688 | 1,250 | 1,430 | [
"DDInter1400",
"DDInter1677"
] | Pazopanib | Sipuleucel-T | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1250,
24,
1430
]
],
[
[
1250,
63,
51
],
[
51,
24,
1430
]
],
[
[
1250,
25,
676
],
[
676,
63,
1430
]
],
[
[
1250,
24,
713
],
[
713,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Pazopanib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib ma... |
DB00331 | DB08930 | 1,645 | 1,459 | [
"DDInter1164",
"DDInter582"
] | Metformin | Dolutegravir | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Moderate | 1 | [
[
[
1645,
24,
1459
]
],
[
[
1645,
21,
28722
],
[
28722,
60,
1459
]
],
[
[
1645,
24,
752
],
[
752,
23,
1459
]
],
[
[
1645,
24,
98
],
[
98,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolutegravir"
]
],
[
[
"Metformin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by ... | Metformin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dolutegravir (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Me... |
DB00651 | DB01221 | 746 | 1,190 | [
"DDInter613",
"DDInter1007"
] | Dyphylline | Ketamine | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
746,
24,
1190
]
],
[
[
746,
21,
28642
],
[
28642,
60,
1190
]
],
[
[
746,
23,
22
],
[
22,
63,
1190
]
],
[
[
746,
24,
1674
],
[
1674,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Dyphylline",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} ... | Dyphylline (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Ketamine (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Dyphylline m... |
DB00277 | DB04861 | 1,031 | 1,592 | [
"DDInter1791",
"DDInter1271"
] | Theophylline | Nebivolol | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Major | 2 | [
[
[
1031,
25,
1592
]
],
[
[
1031,
6,
12523
],
[
12523,
45,
1592
]
],
[
[
1031,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1031,
23,
417
],
[
... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nebivolol"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Nebi... | Theophylline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nebivolol (Compound)
Theophylline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Theophylline may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucr... |
DB00532 | DB08907 | 208 | 1,344 | [
"DDInter1152",
"DDInter280"
] | Mephenytoin | Canagliflozin | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
208,
24,
1344
]
],
[
[
208,
24,
1033
],
[
1033,
63,
1344
]
],
[
[
208,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
208,
63,
251
],
[
251,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone... |
DB00586 | DB00991 | 1,512 | 97 | [
"DDInter537",
"DDInter1358"
] | Diclofenac | Oxaprozin | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
1512,
24,
97
]
],
[
[
1512,
24,
1274
],
[
1274,
24,
97
]
],
[
[
1512,
23,
307
],
[
307,
1,
97
]
],
[
[
1512,
24,
998
],
[
998,
1... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafi... |
DB00073 | DB11601 | 1,394 | 1,270 | [
"DDInter1608",
"DDInter1889"
] | Rituximab | Tuberculin purified protein derivative | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1394,
24,
1270
]
],
[
[
1394,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1394,
25,
1064
],
[
1064,
24,
1270
]
],
[
[
1394,
25,
1259
],
[
12... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Rituximab may lead to a major life threatening interaction when taken with Cladribi... |
DB06186 | DB11921 | 1,439 | 1,019 | [
"DDInter969",
"DDInter492"
] | Ipilimumab | Deflazacort | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1439,
24,
1019
]
],
[
[
1439,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
1439,
64,
126
],
[
126,
24,
1019
]
],
[
[
1439,
24,
1412
],
[
1412... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Ipilimumab may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moder... |
DB09083 | DB12332 | 880 | 1,619 | [
"DDInter996",
"DDInter1626"
] | Ivabradine | Rucaparib | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
880,
25,
1619
]
],
[
[
880,
64,
1419
],
[
1419,
24,
1619
]
],
[
[
880,
24,
159
],
[
159,
63,
1619
]
],
[
[
880,
25,
823
],
[
823,
... | [
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may ca... | Ivabradine may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause... |
DB01105 | DB01173 | 222 | 358 | [
"DDInter1665",
"DDInter1349"
] | Sibutramine | Orphenadrine | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
222,
24,
358
]
],
[
[
222,
24,
272
],
[
272,
24,
358
]
],
[
[
222,
64,
939
],
[
939,
1,
358
]
],
[
[
222,
24,
820
],
[
820,
63,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Sibutramine may lead to a major life threatening interaction when taken with Benzphetamine and Be... |
DB04951 | DB08870 | 187 | 850 | [
"DDInter1477",
"DDInter228"
] | Pirfenidone | Brentuximab vedotin | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
187,
24,
850
]
],
[
[
187,
63,
267
],
[
267,
24,
850
]
],
[
[
187,
24,
1033
],
[
1033,
63,
850
]
],
[
[
187,
25,
445
],
[
445,
6... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib ... |
DB06817 | DB09407 | 809 | 853 | [
"DDInter1563",
"DDInter1114"
] | Raltegravir | Magnesium chloride | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
809,
24,
853
]
],
[
[
809,
63,
544
],
[
544,
24,
853
]
],
[
[
809,
25,
460
],
[
460,
63,
853
]
],
[
[
809,
25,
286
],
[
286,
24,... | [
[
[
"Raltegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Raltegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate... | Raltegravir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Raltegravir may lead to a major life threatening interaction when taken with Magnesium ca... |
DB08880 | DB15044 | 1,510 | 631 | [
"DDInter1771",
"DDInter1738"
] | Teriflunomide | Tafasitamab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytoto... | Major | 2 | [
[
[
1510,
25,
631
]
],
[
[
1510,
64,
4
],
[
4,
24,
631
]
],
[
[
1510,
25,
270
],
[
270,
24,
631
]
],
[
[
1510,
63,
597
],
[
597,
24,... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafasitamab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Oma... | Teriflunomide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Teriflunomide may lead to a major life threatening interaction when taken with Ocrelizumab an... |
DB00631 | DB00691 | 372 | 1,058 | [
"DDInter405",
"DDInter1237"
] | Clofarabine | Moexipril | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
372,
24,
1058
]
],
[
[
372,
63,
1638
],
[
1638,
1,
1058
]
],
[
[
372,
24,
743
],
[
743,
1,
1058
]
],
[
[
372,
24,
954
],
[
954,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Moexipril (Compou... |
DB01229 | DB08873 | 973 | 74 | [
"DDInter1378",
"DDInter221"
] | Paclitaxel (protein-bound) | Boceprevir | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Major | 2 | [
[
[
973,
25,
74
]
],
[
[
973,
6,
4973
],
[
4973,
45,
74
]
],
[
[
973,
7,
2874
],
[
2874,
45,
74
]
],
[
[
973,
21,
28821
],
[
28821,
... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevi... | Paclitaxel may lead to a major life threatening interaction when taken with Boceprevir
Paclitaxel (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Paclitaxel (Compound) upregulates CTSL (Gene) and CTSL (Gene) is bound by Boceprevir (Compound)
Paclitaxel (Compound) causes Sepsis (Side Eff... |
DB00381 | DB09065 | 376 | 760 | [
"DDInter79",
"DDInter424"
] | Amlodipine | Cobicistat | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
376,
24,
760
]
],
[
[
376,
63,
1101
],
[
1101,
23,
760
]
],
[
[
376,
24,
723
],
[
723,
24,
760
]
],
[
[
376,
63,
254
],
[
254,
2... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepita... |
DB00978 | DB06663 | 739 | 1,154 | [
"DDInter1084",
"DDInter1398"
] | Lomefloxacin | Pasireotide | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
739,
25,
1154
]
],
[
[
739,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
739,
62,
112
],
[
112,
23,
1154
]
],
[
[
739,
24,
1385
],
[
1385,
... | [
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caus... | Lomefloxacin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB00238 | DB09570 | 188 | 1,480 | [
"DDInter1285",
"DDInter1002"
] | Nevirapine | Ixazomib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
188,
24,
1480
]
],
[
[
188,
24,
98
],
[
98,
24,
1480
]
],
[
[
188,
25,
1017
],
[
1017,
63,
1480
]
],
[
[
188,
24,
214
],
[
214,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Nevirapine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a mode... |
DB11799 | DB14520 | 627 | 1,229 | [
"DDInter205",
"DDInter1785"
] | Bictegravir | Tetraferric tricitrate decahydrate | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Major | 2 | [
[
[
627,
25,
1229
]
],
[
[
627,
63,
72
],
[
72,
24,
1229
]
],
[
[
627,
25,
428
],
[
428,
62,
955
],
[
955,
23,
1229
]
],
[
[
627,
63... | [
[
[
"Bictegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Bictegravir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
... | Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Bictegravir may lead to a major life threatening interaction when taken with Ferrous ... |
DB01229 | DB10343 | 973 | 962 | [
"DDInter1378",
"DDInter160"
] | Paclitaxel (protein-bound) | Bacillus calmette-guerin substrain tice live antigen | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
973,
25,
962
]
],
[
[
973,
64,
1057
],
[
1057,
25,
962
]
],
[
[
973,
24,
1213
],
[
1213,
25,
962
]
],
[
[
973,
24,
270
],
[
270,
... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Paclitaxel may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Paclitaxel may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin... |
DB00845 | DB14568 | 1,490 | 982 | [
"DDInter406",
"DDInter1000"
] | Clofazimine | Ivosidenib | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1490,
25,
982
]
],
[
[
1490,
23,
112
],
[
112,
23,
982
]
],
[
[
1490,
63,
543
],
[
543,
24,
982
]
],
[
[
1490,
24,
28
],
[
28,
2... | [
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lo... |
DB00758 | DB01088 | 1,347 | 714 | [
"DDInter413",
"DDInter908"
] | Clopidogrel | Iloprost | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1347,
24,
714
]
],
[
[
1347,
23,
539
],
[
539,
62,
714
]
],
[
[
1347,
63,
383
],
[
383,
24,
714
]
],
[
[
1347,
24,
1479
],
[
1479,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Iloprost
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pent... |
DB01105 | DB06754 | 222 | 707 | [
"DDInter1665",
"DDInter471"
] | Sibutramine | Danaparoid | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
222,
24,
707
]
],
[
[
222,
63,
863
],
[
863,
24,
707
]
],
[
[
222,
25,
41
],
[
41,
63,
707
]
],
[
[
222,
25,
901
],
[
901,
24,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Sibutramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran ... |
DB11986 | DB12332 | 484 | 1,619 | [
"DDInter648",
"DDInter1626"
] | Entrectinib | Rucaparib | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
484,
24,
1619
]
],
[
[
484,
62,
222
],
[
222,
23,
1619
]
],
[
[
484,
64,
307
],
[
307,
23,
1619
]
],
[
[
484,
23,
907
],
[
907,
... | [
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Entrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Entrectinib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a m... |
DB00445 | DB14783 | 322 | 287 | [
"DDInter655",
"DDInter574"
] | Epirubicin | Diroximel fumarate | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
322,
24,
287
]
],
[
[
322,
63,
1101
],
[
1101,
24,
287
]
],
[
[
322,
24,
384
],
[
384,
24,
287
]
],
[
[
322,
23,
1307
],
[
1307,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib an... |
DB00250 | DB08899 | 10 | 129 | [
"DDInter475",
"DDInter649"
] | Dapsone | Enzalutamide | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
10,
24,
129
]
],
[
[
10,
6,
8374
],
[
8374,
45,
129
]
],
[
[
10,
21,
29247
],
[
29247,
60,
129
]
],
[
[
10,
1,
1247
],
[
1247,
2... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Dapsone (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Enzalutamide (Compound)
Dapsone (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction ... |
DB06674 | DB13985 | 908 | 546 | [
"DDInter837",
"DDInter1108"
] | Golimumab | Lutetium Lu 177 dotatate | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Major | 2 | [
[
[
908,
25,
546
]
],
[
[
908,
63,
66
],
[
66,
24,
546
]
],
[
[
908,
64,
1683
],
[
1683,
24,
546
]
],
[
[
908,
25,
270
],
[
270,
24,... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Golimumab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinu... |
DB00377 | DB08868 | 1,494 | 1,011 | [
"DDInter1382",
"DDInter737"
] | Palonosetron | Fingolimod | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1494,
25,
1011
]
],
[
[
1494,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1494,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
1494,
23,
1247
],
[
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Palonosetron (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects... |
DB01211 | DB05316 | 609 | 749 | [
"DDInter393",
"DDInter1467"
] | Clarithromycin | Pimavanserin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Major | 2 | [
[
[
609,
25,
749
]
],
[
[
609,
62,
112
],
[
112,
23,
749
]
],
[
[
609,
63,
1264
],
[
1264,
24,
749
]
],
[
[
609,
25,
392
],
[
392,
2... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimavanserin"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin a... |
DB01233 | DB11642 | 1,311 | 938 | [
"DDInter1197",
"DDInter1480"
] | Metoclopramide | Pitolisant | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1311,
24,
938
]
],
[
[
1311,
24,
760
],
[
760,
24,
938
]
],
[
[
1311,
62,
1010
],
[
1010,
24,
938
]
],
[
[
1311,
63,
1233
],
[
1233,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine and ... |
DB00374 | DB01364 | 1,061 | 22 | [
"DDInter1852",
"DDInter650"
] | Treprostinil | Ephedrine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
1061,
24,
22
]
],
[
[
1061,
24,
1445
],
[
1445,
1,
22
]
],
[
[
1061,
18,
3576
],
[
3576,
45,
22
]
],
[
[
1061,
18,
1954
],
[
1954,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Treprostinil (Compound) downregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Ephedrine (Compound)
Treprostinil (Compound) downregulates COG2 (Gene... |
DB00439 | DB09073 | 289 | 951 | [
"DDInter341",
"DDInter1379"
] | Cerivastatin | Palbociclib | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
289,
24,
951
]
],
[
[
289,
24,
1476
],
[
1476,
63,
951
]
],
[
[
289,
24,
467
],
[
467,
24,
951
]
],
[
[
289,
63,
134
],
[
134,
2... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and ... |
DB00700 | DB09098 | 312 | 98 | [
"DDInter656",
"DDInter1700"
] | Eplerenone | Somatrem | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
312,
24,
98
]
],
[
[
312,
24,
159
],
[
159,
63,
98
]
],
[
[
312,
63,
1573
],
[
1573,
24,
98
]
],
[
[
312,
25,
609
],
[
609,
24,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Pr... |
DB01142 | DB01191 | 1,264 | 1,039 | [
"DDInter593",
"DDInter518"
] | Doxepin | Dexfenfluramine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
1264,
25,
1039
]
],
[
[
1264,
6,
6112
],
[
6112,
45,
1039
]
],
[
[
1264,
63,
211
],
[
211,
23,
1039
]
],
[
[
1264,
24,
1045
],
[
1045,... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dexfenfl... | Doxepin (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dexfenfluramine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Dexfenfluramine
Doxepin may ca... |
DB00361 | DB09048 | 134 | 555 | [
"DDInter1939",
"DDInter1284"
] | Vinorelbine | Netupitant | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
134,
24,
555
]
],
[
[
134,
63,
1101
],
[
1101,
23,
555
]
],
[
[
134,
24,
283
],
[
283,
62,
555
]
],
[
[
134,
25,
384
],
[
384,
6... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedrat... |
DB06228 | DB12141 | 792 | 971 | [
"DDInter1609",
"DDInter817"
] | Rivaroxaban | Gilteritinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
792,
24,
971
]
],
[
[
792,
24,
466
],
[
466,
62,
971
]
],
[
[
792,
24,
1097
],
[
1097,
24,
971
]
],
[
[
792,
63,
1335
],
[
1335,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and ... |
DB06448 | DB06605 | 171 | 1,409 | [
"DDInter1087",
"DDInter108"
] | Lonafarnib | Apixaban | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
171,
25,
1409
]
],
[
[
171,
25,
1670
],
[
1670,
63,
1409
]
],
[
[
171,
63,
86
],
[
86,
24,
1409
]
],
[
[
171,
64,
723
],
[
723,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may... | Lonafarnib may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a ... |
DB01110 | DB11575 | 86 | 1,676 | [
"DDInter1209",
"DDInter841"
] | Miconazole | Grazoprevir | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Moderate | 1 | [
[
[
86,
24,
1676
]
],
[
[
86,
63,
723
],
[
723,
24,
1676
]
],
[
[
86,
24,
1478
],
[
1478,
24,
1676
]
],
[
[
86,
24,
351
],
[
351,
63... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaf... |
DB00773 | DB15091 | 896 | 676 | [
"DDInter702",
"DDInter1901"
] | Etoposide | Upadacitinib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
896,
25,
676
]
],
[
[
896,
63,
1461
],
[
1461,
23,
676
]
],
[
[
896,
24,
1430
],
[
1430,
24,
676
]
],
[
[
896,
24,
1654
],
[
1654,
... | [
[
[
"Etoposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleuc... |
DB00424 | DB01238 | 19 | 673 | [
"DDInter896",
"DDInter118"
] | Hyoscyamine | Aripiprazole | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
19,
24,
673
]
],
[
[
19,
24,
1630
],
[
1630,
1,
673
]
],
[
[
19,
6,
4304
],
[
4304,
45,
673
]
],
[
[
19,
21,
28763
],
[
28763,
6... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Hyoscyamine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Aripiprazole (Compound)
Hyoscyamine (Compound) causes Chest pain (Side Effect) and... |
DB00991 | DB01276 | 97 | 123 | [
"DDInter1358",
"DDInter706"
] | Oxaprozin | Exenatide | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
97,
24,
123
]
],
[
[
97,
63,
1573
],
[
1573,
24,
123
]
],
[
[
97,
24,
1039
],
[
1039,
24,
123
]
],
[
[
97,
1,
939
],
[
939,
24,
... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexf... |
DB00631 | DB01028 | 372 | 1,332 | [
"DDInter405",
"DDInter1179"
] | Clofarabine | Methoxyflurane | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular... | Moderate | 1 | [
[
[
372,
24,
1332
]
],
[
[
372,
24,
1448
],
[
1448,
63,
1332
]
],
[
[
372,
63,
1512
],
[
1512,
24,
1332
]
],
[
[
372,
24,
50
],
[
50,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxyflurane"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Methoxyflurane
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac ... |
DB06777 | DB09122 | 780 | 1,613 | [
"DDInter348",
"DDInter1409"
] | Chenodeoxycholic acid | Peginterferon beta-1a | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
780,
24,
1613
]
],
[
[
780,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
780,
24,
1534
],
[
1534,
63,
1613
]
],
[
[
780,
63,
267
],
[
267,
... | [
[
[
"Chenodeoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Chenodeoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases wh... |
DB00631 | DB15822 | 372 | 69 | [
"DDInter405",
"DDInter1504"
] | Clofarabine | Pralsetinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
372,
24,
69
]
],
[
[
372,
24,
283
],
[
283,
24,
69
]
],
[
[
372,
63,
1648
],
[
1648,
24,
69
]
],
[
[
372,
24,
609
],
[
609,
25,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Al... |
DB00030 | DB00761 | 1,685 | 1,621 | [
"DDInter934",
"DDInter1497"
] | Insulin human | Potassium chloride | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Minor | 0 | [
[
[
1685,
23,
1621
]
],
[
[
1685,
24,
914
],
[
914,
63,
1621
]
],
[
[
1685,
24,
743
],
[
743,
25,
1621
]
],
[
[
1685,
24,
1414
],
[
1414,
... | [
[
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium chloride"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lisinop... |
DB00749 | DB00945 | 59 | 1,479 | [
"DDInter699",
"DDInter20"
] | Etodolac | Acetylsalicylic acid | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
59,
24,
1479
]
],
[
[
59,
6,
6017
],
[
6017,
45,
1479
]
],
[
[
59,
10,
11666
],
[
11666,
49,
1479
]
],
[
[
59,
54,
19122
],
[
19122,
... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Etodolac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compo... | Etodolac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Acetylsalicylic acid (Compound)
Etodolac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Acetylsalicylic acid (Compound)
Etodolac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacol... |
DB01168 | DB01175 | 1,053 | 318 | [
"DDInter1526",
"DDInter672"
] | Procarbazine | Escitalopram | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
1053,
25,
318
]
],
[
[
1053,
64,
1230
],
[
1230,
1,
318
]
],
[
[
1053,
21,
29276
],
[
29276,
60,
318
]
],
[
[
1053,
63,
597
],
[
597,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Procarbazine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Procarbazine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Escitalopram (Compound)
Procarbazine may cause a moderate interaction t... |
DB01206 | DB14409 | 37 | 1,129 | [
"DDInter1086",
"DDInter867"
] | Lomustine | Human adenovirus e serotype 4 strain cl-68578 antigen | An alkylating agent of value against both hematologic malignancies and solid tumors. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
37,
24,
1129
]
],
[
[
37,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
37,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
37,
63,
134
],
[
134,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"E... | Lomustine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Lomustine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00026 | DB10429 | 1,184 | 200 | [
"DDInter94",
"DDInter282"
] | Anakinra | Candida albicans | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1184,
24,
200
]
],
[
[
1184,
24,
1096
],
[
1096,
24,
200
]
],
[
[
1184,
25,
976
],
[
976,
24,
200
]
],
[
[
1184,
24,
1019
],
[
1019,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Anakinra may lead to a major life threatening interaction when taken with Tofacitinib and Tofa... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.